What are you searching for?

11.03.2020 | Tracker

FDA Tracker: HCPs share migraine and heart treatment approvals

By Nathan Cripps

CREATION Pinpoint’s Drug Launch Tracker shows how healthcare professionals (HCPs) respond to drug launch news, as it happens. The FDA approved over 400 submissions between 11 February 2020 – 10 March 2020, which included medications that are used to treat epilepsy and neuropathic pain, bacterial infections and adults with Cushing’s syndrome.

The most mentioned FDA approvals by HCPs online

BrandCompound(s)ManufacturerBrand mentionsCompound mentionsTotal mentions
NexletolbempedoicEsperion Therapeutics Inc105161
NurtecrimegepantBiohaven Pharma Holding Co Ltd213455
IsturisaosilodrostatNovartis Pharms Corp121628
Nexlizetbempedoic acid;ezetimibeEsperion Therapeutics Inc22426
Vyeptiblaeptinezumab-jjmrLundbeck Seattle Biopharmaceuticals, Inc.02323
TrulicitybladulaglutideEli Lilly And Co02020
DurystbimatoprostAllergan12719
Voltarendiclofenac sodiumGlaxosmithkline Cons18018
PyrimethaminepyrimethamineCerovene Inc10010
AnjesomeloxicamBaudax Bio Inc909
BarhemsysamisulprideAcacia Pharma Ltd358
Patadayolopatadine hydrochlorideNovartis808
Twirllevonorgestrel;ethinyl estradiolAgile Therapeutics Inc707
Albuterolalbuterol sulfatePerrigo Pharms Co606
DextenzdexamethasoneOcular Therapeutix066
Advilibuprofen; acetaminophenPfizer Inc606
ApixabanapixabanDr Reddys Labs Inc505
XareltorivaroxabanJanssen Pharms055
Olopatadineolopatadine hydrochlorideWatson Labs Inc404
Sarclisablaisatuximab-irfcSanofi Aventis Us033
PizensylactitolBraintree Labs303
Metforminmetformin hydrochlorideSaptalis Pharms303
Nicotinenicotine polacrilexDr Reddys Labs Sa303
Ofevnintedanib esylateBoehringer Ingelheim202
Patanololopatadine hydrochlorideNovartis202
Suboxonebuprenorphine hydrochloride; naloxone hydrochlorideIndivior Inc101
TerilcarbamazepineTaro101
Procysbicysteamine bitartrateHorizon Pharma Usa101
Lenvimlenvatinib mesylateEisai Inc101
Nerlynxneratinib maleatePuma Biotech101

Espion’s Nexletol (bempedoic acid) was the most mentioned FDA approval by HCPs this month with 95 mentions. The news of the approval was greeted with HCPs sharing this news saying that it is the ‘first non-statin pill in two decades’ and ‘another tool in our arsenal’. A tweet by Michael Gibson, a US cardiologist, shared an article by STAT news stating that Nexletol could be used to test the market of heart medications. This test will see whether the price of the medication is a barrier in the market.

https://twitter.com/CMichaelGibson/status/1230967904130207746

The second most mentioned FDA approval by HCPs was Nurtec (rimegepant) with 55 mentions. HCPs were positive towards Nurtec saying that it is ‘pretty great to have options’ and ‘another great new weapon’. An article by the American Headache Society sharing the news of the approval and giving information about how Nurtec works was tweeted six times by HCPs.

https://twitter.com/ahsheadache/status/1233474662920806404

We are tracking the HCP reaction to FDA approvals and related topics each month. You can keep up to date with this and other pharmaceutical tracking updates within the Tracking section of CREATION Knowledge, or by signing up to our monthly eJournal.


READ LAST MONTH’S FDA APPROVAL TRACKER:

https://creation.co/knowledge/fda-tracker-novo-nordisks-ozempic-and-rybelsus-the-most-mentioned-approvals/

Methodology notes:

  • Data for this research was analysed from the online Twitter conversations of HCPs talking about FDA approvals in English language (all other languages are available), between February 11th 2020 and March 10th 2020.
  • Between February 11th 2020 and March 10th 2020, 1,291 HCPs shared posts about FDA approvals 1,713 times all over the world.
  • The table refers only to approvals that occurred between February 11th 2020 and March 10th 2020. Mentions of approvals before February 11th were not included.
  • HCPs mention brand and compound names when discussing FDA approvals. Approvals may include multiple brands and compounds.

View all articles >

Meet the Author

Nathan Cripps

Suggested next


11.12.2019 | Article

#WhatHCPsThink: 4 Digital behaviours when HCPs use social media

#WhatHCPsThink: 4 Digital behaviours when HCPs use social media

By Lara Meyer

A CREATION Press Release

07.06.2013 | Press Release

Arrhythmia most talked about subject by doctors in new social media study on heart disease

Arrhythmia most talked about subject by doctors in new social media study on heart disease

View all articles >